Atorvastatin prevents type 2 diabetes mellitus—An experimental study

Madhu, Sri Venkata; Aslam, Mohd; Galav, Vikas; Bhattacharya, Swapan Kumar; Jafri, Aiman Abbas

doi:10.1016/j.ejphar.2014.01.069

Cited by 7 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that after treatment with 10-mg ATV, the blood glucose level and insulin resistance in patients suffering from T2DM with dyslipidemia did not differ greatly, possibly because of the poor orientation of lipid metabolism in patients and also due to the inconsistency in the ATV dose [28]. In addition, a previous study based on the T2DM model ascertained the tendency of ATV to inhibit T2DM progression [29]. Our study was performed in consistency with the following novelties different from previous studies.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and adverse reaction to different doses of atorvastatin in the treatment of type II diabetes mellitus

Jiang

Zheng

2019

Bioscience Reports

View full text Add to dashboard Cite

Background: Type II diabetes mellitus (T2DM), a persistent metabolic disorder, is primarily characterized by insulin resistance, relative insulin deficiency and dyslipidemia. Here, we aimed to investigate whether different doses of atorvastatin (ATV) affect rats with T2DM. A total of 110 Sprague–Dawley rats were successfully established as T2DM models. Methods: First, the total cholesterol, triglyceride (TG), high-/low-/very-low-density lipoprotein cholesterol (HDL-c/LDL-c/VLDL-c), alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine (Cr), apolipoprotein Al (ApoA1) and apolipoprotein B (ApoB) levels in rat serum were analyzed. In addition, cholesteryl ester transfer protein (CETP) and retinol-binding protein 4 (RBP4) were also measured. Then, the incidence of adverse reactions was noted. Finally, the pathological study of liver and pancreatic tissues was performed. Results: Rats administered ATV at the doses of 40 and 80 mg/(kg·day) showed down-regulated TG, LDL-c, ApoB, CETP and RBP4 levels yet up-regulated HDL-c and ApoAl levels. Rats administered ATV at a dose of 80 mg/(kg·day) exhibited a higher incidence of adverse reactions and higher ALT and AST levels but lower BUN and Cr levels, which might affect liver and kidney function. Rats administered ATV at the doses of 40 and 80 mg/(kg·day) demonstrated significantly improved liver injury and pancreatic injury induced by T2DM. Conclusion: These data revealed that ATV could improve the lipid metabolism in T2DM rats and 40 mg/(kg·day) may serve as the optimal dose for the reduction of lipid levels and the incidence of adverse effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and adverse reaction to different doses of atorvastatin in the treatment of type II diabetes mellitus

Jiang

Zheng

2019

Bioscience Reports

View full text Add to dashboard Cite

show abstract

“… 38 Animal study showed atorvastatin could prevent the development of type 2 diabetes in the rat model. 39 Therefore, the risk of new-onset type 2 diabetes in relationship with atorvastatin treatment needs to be long-term follow-up.…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin Treatment for Carotid Intima-Media Thickness in Chinese Patients With Type 2 Diabetes

et al. 2015

View full text Add to dashboard Cite

Impact of atorvastatin on carotid intima-media thickness (CIMT) in patients with type 2 diabetes is still debating.The aim of our study is to investigate atorvastatin as adjuvant treatment on CIMT in Chinese patients with type 2 diabetes by conducting a meta-analysis based on the randomized controlled trials (RCTs).A systematic search of electronic database of the Pubmed, EMBASE, Cochrane Library, VIP database, China National Knowledge Infrastructure, and Wangfang up to January 2015 was conducted. Randomized controlled trials (RCTs) comparing atorvastatin adjuvant treatment to the hypoglycemic therapies or high-dose atorvastatin versus low-dose atorvastatin therapies for patients with type 2 diabetes were selected.A total of 14 RCTs involving 1345 patients were included. Adjuvant treatment with atorvastatin was associated with a significant reduction in CIMT (weighted mean difference [WMD] = −0.17 mm; 95% confidence interval [CI] −0.22 to −0.12). Compared with the low-dose atorvastatin, high-dose atorvastatin treatment was associated with a significant reduction in CIMT (WMD = −0.17 mm; 95% CI: −0.32 to −0.02). Adjuvant treatment with atorvastatin reduced serum total cholesterol, triglyceride, low-density lipoproteins, and high sensitivity C-reactive protein levels. However, atorvastatin had no significant impact on blood glucose levels.This meta-analysis demonstrated that treatment with atorvastatin significantly reduced CIMT in Chinese patients with type 2 diabetes. Moreover, high-dose atorvastatin appeared to have additional benefits in reducing CIMT than the low-dose atorvastatin.

show abstract

“…The statins have recently been shown to exert direct cardiovascular effects independent of their cholesterol-lowering effects. 183 A recent article examined various studies on the diabetogenic potential of statins and recommends that the benefits of statin therapy appear to outweigh the risk of new-onset diabetes and that it would be inappropriate to discontinue statins for prevention of cardiovascular events because of the potential risk of incipient diabetes. 181 However, a recent systematic review has shown an increased risk of new-onset diabetes in patients treated with statins, and there is a link with the dose used; the more potent statins have an increased risk of causing diabetes.…”

Section: Statinsmentioning

confidence: 99%